<DOC>
	<DOCNO>NCT01281917</DOCNO>
	<brief_summary>The investigator want find drug Velcade temsirolimus give together effective treating cancer . Velcade temsirolimus FDA approve individually certain type cancer ( Velcade multiple myeloma mantle cell lymphoma , temsirolimus renal cell carcinoma ) currently approve combination B-cell non-Hodgkin lymphoma . The investigator try find give 2 drug together improve period time patient 's cancer stop slow grow cause symptom .</brief_summary>
	<brief_title>Study Velcade Temsirolimus Relapsed Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Relapsed refractory Bcell nonHodgkin lymphoma include : diffuse large Bcell lymphoma ; primary mediastinal large Bcell lymphoma ; follicular lymphoma ( grade 1 , 2 3 ) ; mantle cell lymphoma ; small lymphocytic lymphoma ; marginal zone lymphoma ; lymphoplasmacytic lymphoma ; Bcell lymphoblastic lymphoma ; Burkitt lymphoma . `` Greyzone '' lymphoma must approve WON Study Chair Principal Investigator prior enrollment . At least one measurable tumor mass ( &gt; 1.5 cm long axis &gt; 1.0 cm short axis ) previously irradiate , grow since previous irradiation . Documented relapse progression follow prior antineoplastic therapy . No clinical document radiographic evidence central nervous system lymphoma . Eastern Cooperative Oncology Group [ ECOG ] performance status 02 . The following clinical laboratory value within 14 day prior enrollment : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109 cell / L Platelets ≥ 100 x 109 cell / L Alanine transaminase ( ALT ) Aspartate transaminase ( AST ) ≤ 3X upper limit normal ( ULN ) Total bilirubin ≤ 2X upper limit normal ( ULN ) . Calculated creatinine clearance ≥40 mL/min ( use CockcroftGault equation ) . Female subject must either postmenopausal least 1 year surgically sterilize , agree practice 2 effective method contraception time sign informed consent form 30 day last dose Velcade , agree completely abstain heterosexual intercourse . Male subject , even surgically sterilize ( ie , status postvasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . Exclusions : Antineoplastic , experimental , radiation therapy within 14 day prior enrollment , 21 day prior Day 1 Cycle 1 . Radioimmunoconjugates within 10 week Day 1 Cycle 1 . Autologous stem cell transplant within 3 month Day 1 Cycle 1 , prior history allogeneic stem cell transplant . Platelet transfusion within 7 day Day 1 Cycle 1 . Ongoing therapy glucocorticoid . Prednisone ≤15 mg per day equivalent allow . Patient Grade 2 great peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Patient hypersensitivity Velcade , boron mannitol . Female subject pregnant breastfeeding . Serious medical psychiatric illness likely interfere participation Diagnosed treat another malignancy within 2 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Prior therapy Velcade temsirolimus . Patients previously treat either Velcade temsirolimus ( ) eligible . Radiation therapy within 3 week randomization . Patients must take follow strong CyP3A inducer study entry : phenytoin , phenobarbital , rifampin , carbamazepin , rifabutin , rifampicin , one week washout period require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>velcade</keyword>
	<keyword>temsirolimus</keyword>
	<keyword>non-hodgkins lymphoma</keyword>
</DOC>